Biotech News
Related news
GRIGRI Bio2026-08-24 14:05 EST
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
XGNExagen2026-07-28 13:00 EST
Exagen Inc. to Participate in Upcoming Investor Conference
AVTXAvalo Therapeutics2026-07-22 11:00 EST
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
EQEquillium, Inc.2026-05-28 20:05 EST
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
KYMRKymera2026-05-27 11:00 EST
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST
Regeneron Announces Investor Conference Presentations
KNSAKiniksa2026-05-29 20:01 EST
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
KNSAKiniksa2026-08-07 20:01 EST
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
ACRSAclaris Therapeutics2026-05-28 12:30 EST
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
GRI Bio
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
Recent company news
GRIGRI Bio2026-08-24 14:05 EST
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRIGRI Bio2026-05-14 13:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-05-14 13:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-05-14 08:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Stock data
- Close
- 1.65 USD
- Market cap
- 3.56M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States